GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Market Cap

PCI Biotech Holding ASA (FRA:4QG) Market Cap : €4.85 Mil (As of Dec. 13, 2024)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). PCI Biotech Holding ASA's share price for the quarter that ended in Jun. 2024 was €0.161. PCI Biotech Holding ASA's Shares Outstanding (EOP) for the quarter that ended in Jun. 2024 was 37.33 Mil. Therefore, PCI Biotech Holding ASA's market cap for the quarter that ended in Jun. 2024 was €6.01 Mil.

PCI Biotech Holding ASA's quarterly market cap declined from Jun. 2023 (€6.41 Mil) to Dec. 2023 (€6.22 Mil) and declined from Dec. 2023 (€6.22 Mil) to Jun. 2024 (€6.01 Mil).

PCI Biotech Holding ASA's annual market cap declined from Dec. 2021 (€50.39 Mil) to Dec. 2022 (€5.48 Mil) but then increased from Dec. 2022 (€5.48 Mil) to Dec. 2023 (€6.22 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. PCI Biotech Holding ASA's Enterprise Value for Today is €2.28 Mil.


PCI Biotech Holding ASA Market Cap Historical Data

The historical data trend for PCI Biotech Holding ASA's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Market Cap Chart

PCI Biotech Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 271.67 95.56 50.39 5.48 6.22

PCI Biotech Holding ASA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Jun24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.48 4.95 6.41 6.22 6.01

Competitive Comparison of PCI Biotech Holding ASA's Market Cap

For the Biotechnology subindustry, PCI Biotech Holding ASA's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Market Cap distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Market Cap falls into.



PCI Biotech Holding ASA Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

PCI Biotech Holding ASA's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=€0.1666*37.3264
=€6.22

PCI Biotech Holding ASA's Market Cap for the quarter that ended in Jun. 2024 is calculated as

Market Cap (Q: Jun. 2024 )=Share Price (Q: Jun. 2024 )*Shares Outstanding (EOP) (Q: Jun. 2024 )
=€0.161*37.3264
=€6.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCI Biotech Holding ASA  (FRA:4QG) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


PCI Biotech Holding ASA Market Cap Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines